At page 15, line 5, replace "mwtL" with --metal--.

At page 20, line 18, replace "radiopharmacueticals" with --radiopharmaceuticals--.

At page 40, line 30, replace "euthanasing" with --euthanizing--.

At page 43, line 2, replace "filed" with --field--.

At page 45, line 13, replace "resuspened" with --resuspended--.

At page 47, line 21, replace "radiotheraprutic" with --radiotherapeutic--.

## IN THE CLAIMS

Please cancel claims 9,11-25, 27, 30, and 32-36 without prejudice.

Amend claim 1 to read:

1(amended). A reagent for preparing a radiopharmaceutical agent, the reagent comprising [that is] a monoamine, diamide, thiol-containing metal chelator covalently linked to a targeting moiety

Amend claim 2 to read:

2 (amended). A reagent [of] according to claim 1, wherein the metal chelator [is selected form the group consisting of:

(i) a group having the] has a formula:

Contol

[and (ii) a group having the formula:

wherein:

n, m and p are each independently 0 or 1,

each R' is independently H, lower alkyl, hydroxyalkyl (C2-C4), or alkoxyalkyl (C2-

 $C_4);$ 

each R is/independently H or R", where R" is substituted or unsubstituted lower alkyl or phenyl not comprising a thiol group;

one R of R' is L, wherein when an R' is L, -NR'<sub>2</sub> is an amine; and L is a bivalent linking group linking the chelator to the targeting moiety.



Amend claim 3 to read:

3 (amended). A [composition of] reagent according to claim 2, wherein the metal chelator has [the] a formula:

wherein:

 $R^1$  and  $R^2$  are each independently H, lower alkyl, hydroxyalkyl ( $C_2$ - $C_4$ ) or alkoxyalkyl ( $C_2$ - $C_4$ );

R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> are independently H, substituted or unsubstituted lower alkyl or phenyl not comprising a thiol group;

 $R^7$  and  $R^8$  are each independently H, lower alkyl, lower hydroxyalkyl or lower alkoxyalkyl; L is a bivalent linking moiety; and

Z is a targeting moiety.

Amend claim 4 to read:

4 (amended). A [composition of ] reagent according to claim 2, wherein the metal chelator has [the] a formula:

CI



wherein:

 $R^1$  and  $R^2$  are each independently H, lower alkyl, hydroxyalkyl ( $C_2$ - $C_4$ ), or alkoxyalkyl ( $C_2$ - $C_4$ );

 $R^3$ ,  $R^4$ ,  $R^5$ , and  $R^6$  are independently H, substituted or unsubstituted lower alkyl or phenyl not comprising a thiol group, and one of  $R^3$ ,  $R^4$ ,  $R^5$ , and  $R^6$  is Z-L-( $CR_2$ )<sub>n</sub>-, where n is an integer from 1 to 6 and each R is independently H, lower alkyl, or substituted lower alkyl;

R<sup>7</sup> and R<sup>8</sup> are each independently H, lower alkyl, lower hydroxyalkyl or lower alkoxyalkyl;

L is a bivalent linking moiety;

Z is a targeting moiety; and

X is -NH<sub>2</sub>, -NR<sup>1</sup>R<sup>2</sup>, or -NR<sup>1</sup>-Y, where Y is an amino acid, an amino acid amide, or a peptide of from 2 to about 20 amino acids.

Amend claim 5 to read:

5 (amended). A [composition of] reagent according to claim 4, wherein the metal chelator

has [the] a formula:

wherein:

 $R^1$  and  $R^2$  are each independently H, lower alkyl, hydroxyalkyl ( $C_2$ - $C_4$ );

R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently H, substituted or unsubstituted lower alkyl or phenyl not comprising a thiol group;

golf .

W)

USSN 08/253,973 December 15, 1997 page 6

n is an integer from 1 to 6;

L is a bivalent linking moiety; and

Z is a targeting moiety.

Amend claim 6 to read:

6. A [composition of] reagent according to claim 5, wherein the metal chelator has [the] a formula:

wherein:

L is a linker group; and

Z is a targeting moiety.

Amend claim 7 to read:

7 (amended). A [composition of] reagent according to claim 2, wherein the metal chelator is selected from the group consisting of:

(amino acid)<sup>1</sup>-(amino acid)<sup>2</sup>-cysteine-,

(amino acid)<sup>1</sup>-(amino acid)<sup>2</sup>-isocysteine-,

(amino acid)<sup>1</sup>-(amino acid)<sup>2</sup>-homocysteine-,

(amino acid)<sup>1</sup>-(amino acid)<sup>2</sup>-penicillamine-,

(amino acid)<sup>1</sup>-(amino acid)<sup>2</sup>-2-mercaptoethylamine-,

(amino acid)<sup>1</sup>-(amino acid)<sup>2</sup>-2-mercaptopropylamine-,

(amino acid)<sup>1</sup>-(amino acid)<sup>2</sup>-2-mercapto-2-methylpropylamine-.

(amino acid)<sup>1</sup>-(amino acid)<sup>2</sup>-3-mercaptopropylamine-,

wherein:

(amino acid) is a primary α- or β-amino acid not comprising a thiol, and wherein the [chelating group] chelator is attached to a targeting moiety via a covalent bond with [the] a carboxyl terminus of the [chelating group] chelator or via a side chain on one [of the amino acid groups] (amino acid).

Amend claim 8 to read:

8 (amended). A [composition of] reagent according to claim 7, wherein (amino acid) is either a  $\alpha,\omega$ - or  $\beta,\omega$ -diamino acid [wherein the] having a free  $\alpha$ -amine or  $\beta$ -amine [is a free amine].

Amend claim 10 to read:

10 (amended). A [composition of] reagent according to claim 2, wherein the chelating group has a formula selected from the group consisting of:

Gly-Gly-Cys-

Arg-Gly-Cys-

-(ε-Lys)-Gly-Cys-

-(δ-Orn)-Gly-Cys-

-(γ-Dab)-Gly-Cys-

and

-(β-Dap)-Gly-Cys-.

Amend claim 26 to read:

26 (amended). A composition of matter comprising a monoamine, diamide, thiolcontaining metal chelator.

Amend claim 31 to read: